A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02693067 |
Recruitment Status :
Active, not recruiting
First Posted : February 26, 2016
Last Update Posted : October 8, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neuroendocrine Tumors Metastatic to the Liver | Drug: Rose bengal disodium | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products |
Study Start Date : | July 2016 |
Estimated Primary Completion Date : | March 2021 |
Estimated Study Completion Date : | May 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: PV-10
Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
|
Drug: Rose bengal disodium
Percutaneous intralesional injection to NET tumor
Other Name: PV-10 |
- Number of Participants with Adverse Events [ Time Frame: 28 days ]Incidence of Systemic and Locoregional Adverse Events will be Coded and Tabulated
- Objective Response Rate (ORR) [ Time Frame: 6 months ]Response of Injected Target and Measurable Bystander Lesions (if present) will be Tabulated
- Target Lesion Somatostatin Receptor (SSTR) Expression [ Time Frame: 6 months ]Change in SSTR Expression will be Assessed vs Baseline Values
- Change in Neuroendocrine Tumor Biomarkers [ Time Frame: 6 months ]Change in Chromogranin A (CgA) and/or 5-Hydroxyindole Acetic Acid (5-HIAA) will be Assessed vs Baseline Values
- Reduction in Major Symptoms [ Time Frame: 6 months ]Change in Major Symptoms (Diarrhea and Flushing) will be Separately Assessed using European Organization for Research and Treatment of Cancer QLQ-C30 and GI.NET21 Symptom Scores vs Baseline Values
- Reduction in Other Symptoms [ Time Frame: 6 months ]Change in Other Symptoms (including Bronchoconstriction and Abdominal Cramping) will be Separately Assessed using QLQ-C30 and GI.NET21 Symptom Scores vs Baseline Values
- Change in Peripheral Blood Mononuclear Cells (PBMC) [ Time Frame: 28 days ]Change in PBMC will be Assessed vs Baseline Values

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18 years or older, males and females.
- Histologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, NET tumors metastatic to the liver that are not amenable at the time of enrolment to resection, transplant or other potentially curative therapy. Patients must have at least one common NET symptom (European Organization for Research and Treatment of Cancer GI.NET21 instrument score of 2 or more at baseline) including: flushing, diaphoresis, diarrhea, abdominal discomfort, hyperacidity, dyspnea or palpitations.
- The Target Lesion(s) must be determined to be amenable to percutaneous injection by the treating physician.
- The Target Lesion(s) must have measurable disease, defined as a unidimensionally measurable lesion ≥ 1.0 cm in longest diameter by helical computed tomography (CT); the maximum diameter of any Target Lesion should be ≤ 3.9 cm. These lesions should also overexpress SSTR. If the lesion is negative on positron emission tomography-computed tomography (PET/CT), there is no need to perform further PET/CT scans.
- Performance status of Karnofsky scale 60%-100% or Eastern Cooperative Oncology Group (ECOG) performance scale 0-2.
- Life expectancy ≥ 6 Months.
-
Hematopoietic Function
- White blood cells (WBC) ≥ 2,500/mm3.
- Absolute neutrophil count (ANC) ≥ 1000/mm3.
- Hemoglobin ≥ 8 g/dL.
- Platelet count ≥ 50,000/mm3.
- Coagulation: international normalized ratio (INR) ≤ 1.3.
-
Blood Chemistry
- Aspartate transaminase (AST) and alanine transaminase (ALT) < 5 times Upper Limit of Normal (ULN).
- Alkaline phosphatase (ALP) < 5 times ULN.
- Bilirubin ≤ 1.5 times ULN.
- Creatinine ≤ 1.5 times ULN and estimated glomerular filtration rate (eGFR) ≥ 50.
-
Thyroid Function
• Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum thyroxine) and TSH (serum thyrotropin) ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 abnormality.
-
Renal Function
• Subjects must have adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease, see 8 above.
-
Cardiovascular Function
• Subjects must have adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease. All subjects must have a cardiac echo performed within 12 months to exclude tricuspid incompetence ("carcinoid heart syndrome").
-
Respiratory Function
• Subjects must have adequate respiratory function in the opinion of the Investigator with no clinically significant uncontrolled respiratory disease.
-
Immunological Function
• Subjects must have adequate immune system function in the opinion of the Investigator with no known immunodeficiency disease.
-
Long Acting Somatostatin Analogs
• Subjects on long acting somatostatin analogs must be stable on treatment. Somatostatin analogs are to be continued throughout the study period.
- Informed Consent: Signed by the subject prior to screening.
Exclusion Criteria:
- Target Lesion(s) must not be contiguous with, encompass or infiltrate major blood vessels.
- Liver metastases amenable to resection, transplant or other potentially curative therapy.
- Subjects who have received hepatic surgery, ablation or chemoembolization within 4 weeks of PV-10 administration.
- Radiation Therapy • Subjects who have received hepatic radiation within 4 weeks of PV-10 administration.
-
Chemotherapy
• Subjects who have received chemotherapy within 4 weeks of PV-10 administration (6 weeks for nitrosoureas or mitomycin C).
-
Investigational Agents
• Subjects who have received investigational agents within 4 weeks (or 5 half-lives) of PV-10 administration.
-
Phototoxic or Photosensitizing Agents
• Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of PV-10 administration.
-
Concurrent or Intercurrent Illness
- Subjects with significant concurrent or intercurrent illness, psychiatric disorders or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise their safety or compliance or interfere with interpretation of the study.
- Subjects with uncontrolled thyroid disease or cystic fibrosis.
- Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological (with the exception of the presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine, or central nervous system disorders.
- Current encephalopathy or current treatment for encephalopathy.
- A documented variceal hemorrhage within 4 months of screening.
- History of human immunodeficiency virus or acquired immune deficiency syndrome.
- The clinical or radiological presence of ascites.
-
Pregnancy
- Female subjects who are pregnant or lactating.
- Female subjects who have positive serum pregnancy test taken within 7 days of PV-10 administration.
- Fertile subjects who are not using effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02693067
Australia, South Australia | |
The Queen Elizabeth Hospital | |
Woodville, South Australia, Australia, 5011 |
Study Director: | Eric Wachter, Ph.D. | Provectus Biopharmaceuticals, Inc. |
Responsible Party: | Provectus Biopharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT02693067 |
Other Study ID Numbers: |
PV-10-NET-01 |
First Posted: | February 26, 2016 Key Record Dates |
Last Update Posted: | October 8, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue |